Peptide immobilization on calcium alginate beads: applications to antibody purification and assay

Calcium Alginate Bead-mediated Enhancement of the Selective Recovery of a Lead Novel Antifungal Bacillomycin Variant

In the pursuit of new antifungal compounds, five coproduced lipopeptide variants (AF₁ to AF₅) from wild-type Bacillus subtilis RLID 12.1 were identified in our previous study. Out of five, AF₄ was identified as a novel lead molecule belonging to the bacillomycin family showing less cytotoxicity at its respective minimum inhibitory concentrations (MIC) evaluated against 81 strains of Candida and Cryptococcus species (including clinical isolates); besides this, AF₄ purified in the present study exhibited encouraging MIC values against 10 clinical mycelial fungi. Aiming for a selective production augmentation of AF₄ lipopeptide variant, a new fermentation media comprising malt extract (1.01%), dextrose (0.55%), peptone (1.79%), MnSO₄ (2 mM), and NaCl (0.5%) was formulated. Maximum production of 954.8 ± 10.8 mg/L was achieved with 44% selectivity at 30 °C compared to unoptimized conditions (186.4 ± 6.1 mg/L). Use of calcium alginate beads in the formulated media during the onset of lipopeptide production resulted in an augmentation in the selectivity of the most efficacious AF₄ variant to about 72% presumably due to attenuation of other coproduced lipopeptide variants AF₁ and AF₂. Difference in yield of lipopeptides varied with bead size, bead preparation ratios, and sodium alginate concentrations. Use of Ca-alginate beads in the upstream production process of the lead AF₄ variant may be considered as a novel strategy to address the potential challenge that may arise during the scale-up and downstream processing steps. Another significant finding derived from the study is that the proportion of bacillomycin variants of B. subtilis RLID 12.1 could be controlled by temperature and metal ions under static and shaking conditions.

Plant viral elongated nanoparticles modified for log-increases of foreign peptide immunogenicity and specific antibody detection

Elongated and flexuous recombinant nanoparticles were derived from Turnip mosaic virus to be used as bioscaffolds for increased peptide immunogenicity and peptide-specific antibody sensing. For this purpose, a 20-amino acid peptide derived from human vascular endothelial growth factor receptor 3 (VEGFR-3) was fused to the N-terminal region of Turnip mosaic virus coat protein (CP) by genetic insertion. The insertion was between codons corresponding to the first and second amino acids of the CP in two versions of a previously reported virus-derived vector. Systemic infections of two genetic constructs were achieved in two different plant hosts. The construct proved stable upon successive passages and generated virus nanoparticles identifiable under the electron microscope. The chimeric structures held the VEGFR-3 peptide. Purified VER3 nanoparticles were used to immunize mice, whose sera showed log increases of antibodies against the VEGFR-3 peptide when compared with mice immunized with peptide alone, thus providing the first quantitative data on the potential of elongated flexuous viruses for peptide immunogenicity increases. Purified VER3 nanoparticles also showed log increases in their ability to detect VER3 antibodies in sera, when used as reagents in ELISA assays, an application also used here for the first time.

Selective in vitro removal of anti-A antibodies by adsorption on encapsulated erythrocyte-ghosts

Large volume plasma exchanges are used for the removal of anti-A or anti-B antibodies from the plasma of patients undergoing transplantation from donors with major ABO incompatibility. Previous works suggest that solid-phase immunoadsorption can be substituted for plasma exchange in situations where antigens can be purified and immobilized on columns through which plasma is percolated. However, the preparation of purified antigens of the ABO system is large quantities is laborious and requires the use of considerable blood volumes. Studies were therefore undertaken to determine the feasibility of an original immunoadsorbent based on porous microparticles prepared by a water/oil/water emulsification-solvent evaporation method, within which erythrocytes-ghosts carrying blood group antigens were entrapped. The decrease of the antibody hemagglutinating titre after adsorption onto encapsulated ghosts suggests that antibodies can cross the polymeric membrane and bind to the antigens. This original approach of using encapsulated antigens for the batchwise removal of antibodies could be extended to affinity chromatography, and immunoadsorption therapy with a chromatographic column linked to an extracorporeal circulation could be considered.